About the Author: Jonathan Govette

CEO/Co-Founder @ Oatmeal Health | AI Lung Cancer Screening | Almost Became a Doctor | Engineer | Follow to Share What I’ve Learned Along the Way

I help patients get the care they need earlier, preventing late-stage cancer.

That's been the throughline across three companies and almost 20 years in healthcare. At ReferralMD, we fixed broken referral networks so patients didn't fall through the cracks. At Oatmeal Health, it's lung cancer: building the diagnostic and screening infrastructure so the 85% of cases caught too late get caught early instead. Today as CEO of Oatmeal Health, I lead a team embedding AI into radiology workflows to turn routine lung CT scans into reimbursable cancer risk assessments. We partner with FQHCs to reach underserved communities, and with health systems and payers to make early detection economically sustainable. Think HeartFlow or Cleerly, but for lungs. Between companies, I advised at Techstars and Plug and Play, mentoring founders building in digital health. That experience shaped how I think about what separates companies that ship from companies that stall: distribution, reimbursement, and clinical trust, not just technology. I'm a CancerX alumnus, a 3x healthcare founder, and someone who believes the biggest problems in cancer aren't scientific. They're operational. We're hiring mission-driven builders at Oatmeal Health. If you want to work on something that matters, reach out. When I'm not working, I'm traveling, mentoring, and keeping up with one very energetic husky. 🐾 Substack - The Oatmeal Bite: Millions of patients get less care because of who they are, where they live, or how they look. I'm fighting to change that. CEO @OatmealHealth, a startup built for the underserved. The Oatmeal Bite: intel for clinicians, investors, and advocates. Jonathan Govette CEO of Oatmeal Health Substack: https://oatmealhealthjonathangovette.substack.com/

Screening for Lung Cancer With Low-Dose Computed Tomography: An Evidence Review for the U.S. Preventive Services Task Force

By |June 23rd, 2020|

Summary of Evidence Table 11 provides a summary of the main findings in this evidence review organized by KQ along with a description of consistency, precision, quality, limitations, the strength of evidence, and applicability. Evidence for Benefits and Harms of Screening For the benefits of screening, the good-quality NLST demonstrated a reduction in lung cancer mortality and all-cause mortality with three rounds of annual LDCT screening compared with CXR. Its results indicate an NNS of 323 to prevent one lung cancer death over 6.5 years of follow-up. The fair-quality NELSON trial also demonstrated a reduction in lung cancer mortality, but not all-cause mortality, with four rounds of LDCT screening with increasing intervals; its results indicate a NNS of 130 to ...

Read More
Oatmeal Health is an AI-powered cancer screening platform that combines care navigation, radiology risk tools, and embedded care teams to improve outcomes and advance inclusive research.

  • 650 Castro Street, Ste 120, PMB 93339, Mountain View, Ca 94041

  • (669)-247-2898

Services

Resources

Company

Legal

© 2026

LungAI is a medical device pending FDA 510(k) clearance. It is not yet FDA-cleared or commercially available. All clinical performance data reflects retrospective studies on held-out datasets. Results may differ in prospective clinical use. Oatmeal Health, Inc. is not required to register as a medical device establishment under 21 CFR Part 807 prior to commercial distribution.